ScaleReady’s Work to Make Cell and Gene Therapy Practical and Viable

This week, CancerNetwork spoke with Josh Ludwig, Global Director of Commercial Operations at ScaleReady, about how this joint venture between industry leaders launched in January, is uniquely positioned to make cell and gene therapy practical and viable.

Ludwig elaborated on how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also discussed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and what’s next for ScaleReady.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.